Anlotinib plus Epirubicin Followed by Anlotinib Maintenance as First-line Treatment for Advanced Soft-tissue Sarcoma: An Open-label, Single-arm, Phase II Trial.
Clin Cancer Res
; 28(24): 5290-5296, 2022 12 15.
Article
in En
| MEDLINE
| ID: mdl-36228149
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Quinolines
/
Sarcoma
/
Soft Tissue Neoplasms
/
Anemia
/
Leukopenia
Limits:
Adolescent
/
Humans
Language:
En
Journal:
Clin Cancer Res
Journal subject:
NEOPLASIAS
Year:
2022
Document type:
Article
Country of publication: